UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 2054	19
FORM 8-K	

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 16, 2007

USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter)

Commission File No. 0-21116

Utah 87-0500306
(State or other jurisdiction of incorporation) (IRS Employer Identification Number)

3838 West Parkway Boulevard Salt Lake City, Utah 84120 (Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On October 16, 2007, USANA Health Sciences, Inc. issued a press release announcing its financial results for the third quarter and nine months ended September 29, 2007. The release also announced that executives of the company would discuss these results with investors on a conference call broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. A copy of the press release is furnished herewith as Exhibit 99 to this Current Report on Form 8-K and is incorporated herein by reference. The company will also post this document on its corporate website, www.usanahealthsciences.com.

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99 Press release issued by USANA Health Sciences, Inc. dated October 16, 2007 (furnished herewith).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

USANA HEALTH SCIENCES, INC.

By: /s/ Gilbert A. Fuller
----Gilbert A. Fuller,
Chief Financial Officer

Date: October 16, 2007

3

USANA Health Sciences Announces Third Quarter 2007 Financial Results

- -- Earnings Per Share Increased 25.0%, Year-over-Year, to \$0.70 --
- -- Net Sales Increased 15.5%, Year-over-Year, to \$106.2 Million --

SALT LAKE CITY--(BUSINESS WIRE)--Oct. 16, 2007--USANA Health Sciences, Inc. (NASDAQ: USNA) today announced financial results for the fiscal third quarter ending September 29, 2007.

Financial Performance

Net sales in the third quarter of 2007 increased by 15.5% to \$106.2 million, compared with \$92.0 million in the third quarter of the prior year. Net sales growth for the third quarter of 2007 resulted primarily from a 24.1% net increase in the number of active Associates, meaning those who have purchased products directly from the Company in the preceding three months, either for personal consumption or for resale. Foreign currency fluctuations accounted for 3.4 percentage points of the year-over-year increase in net sales for the third quarter of 2007.

Earnings from continuing operations in the third quarter of 2007 grew by 7.5% to \$17.3 million, or 16.3% of net sales, compared with \$16.1 million, or 17.5% of net sales, in the third quarter of the prior year. Earnings per share from continuing operations increased by 25.0% in the third quarter of 2007 to \$0.70 per share, compared with \$0.56 per share in the third quarter of the prior year. This increase was in part due to aggressive stock repurchases and a lower than expected effective tax rate of 31.4%, offsetting higher Selling General and Administrative expenses.

For the nine-month period ended September 29, 2007, consolidated net sales were \$314.4 million, an increase of 17.7%, compared with \$267.0 million in the first nine months of 2006. Earnings per share from continuing operations increased 22.7% in the first nine months of 2007 to \$2.00, compared with \$1.63 in the first nine months of 2006.

During the third quarter of 2007, the Company repurchased 180 thousand shares for an investment of \$6.6 million. During the first nine months of 2007, the Company repurchased approximately 1.9 million shares for an investment of about \$80 million. As of the end of the third quarter, there was about \$50 million remaining under the current stock buyback authorization.

Regional Results

During the third quarter of 2007, net sales in North America, the Company's most mature region, increased by 10.1% to \$66.6 million, compared with the third quarter of the prior year. This growth was driven primarily by a 16.7% net improvement in the number of active Associates in this region to 105,000. Along with double-digit growth in Canada, sales in Mexico increased by 19.3% over the third quarter of last year.

"We are pleased to have achieved double-digit growth in the number of active Associates and in net sales in the North American region," said Dave Wentz, the Company's President. "Both the Canadian and Mexican markets have contributed to this region's strong sales growth."

During the third quarter of 2007, net sales in the Asia Pacific region increased by 25.7% to \$39.6 million, compared with the third quarter of the prior year. The growth in this region was led by double-digit, year-over-year growth in Hong Kong and the Australia-New Zealand markets. Malaysia continues to show steady growth as a new market, contributing \$4.9 million of incremental revenue in the third quarter, an 8.6% increase, compared with the second quarter. The number of active Associates in the Asia Pacific region increased by

36.4% to 75,000, compared with 55,000 in the third quarter of the prior year. The number of Associates in our newest market, Malaysia, grew to 12,000 in just its third quarter of operations.

"The Asia Pacific region continues to be a healthy market for USANA," continued Wentz. "This region has been contributing an increasing share of our growth, led by Hong Kong and Australia-New Zealand, and we anticipate that the Malaysian market will play an increasingly important role in this region. We continue to focus the majority of our efforts on solidifying and growing our 13 core markets."

Outlook

Today, the Company is providing financial guidance for the fourth quarter of 2007 and its initial look at the full year 2008. Based on its current business trends, the Company believes that net sales for the fourth quarter of 2007 will be between \$108 million and \$110 million, a growth rate of 10% to 12%, compared with the prior year fourth quarter. Earnings per share are expected to be between \$0.66 and \$0.68 for the fourth quarter of 2007. Accordingly, for the year 2007, sales are now expected to be between \$422 million and \$424 million, excluding revenues from our discontinued third-party contract manufacturing business, with earnings per share between \$2.66 and \$2.68. Additionally, in the Company's first look at full-year 2008, we believe that both net sales and earnings per share will grow 10% to 13%, compared with the full-year 2007. These earnings per share estimates assume an effective tax rate of approximately 36.0% for the fourth quarter of 2007 and for the full-year 2008.

Gilbert A. Fuller, the Company's executive vice president and chief financial officer, said, "Our strategy of supporting our Associates both domestically and internationally, continues to pay off and produce strong financial results. Going forward, we likely will continue to buy back shares as a way of returning value to our shareholders. We are proud to offer the finest nutritional and personal care products in the industry."

Conference Call

USANA will hold a conference call and webcast to discuss this announcement with investors on Wednesday, October 17, 2007 at 11:00 AM ET. Investors may listen to the call by accessing USANA's website at http://www.usanahealthsciences.com.

About USANA

USANA develops and manufactures high quality nutritional, personal care, and weight management products that are sold directly to Preferred Customers and Associates throughout the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Netherlands, and the United Kingdom. More information on USANA can be found at http://www.usanahealthsciences.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with our international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

(In thousands, except per share data)

	Quarter Ended	
	30-Sep-06 29-Sep-07	
	(Unaudited) (Unaudited)	
Net sales Cost of sales	\$ 91,967 \$106,181 20,274 21,960	
Gross profit	71,693 84,221	
Operating expenses Associate incentives Selling, general and admini Research and development	36,994 43,021 istrative 17,798 23,053 830 864	
Earnings from operations	16,071 17,283	
Other income	65 (270)	
Earnings before income ta	xes 16,136 17,013	
Income taxes	5,698 5,350	
Income from continuing ope	erations 10,438 11,663	
Income (Loss) from discontinued operations (215) (405)		
NET EARNINGS	\$ 10,223 \$ 11,258 	
Earnings per share - diluted Continuing operations Discontinued operations	\$ 0.56 \$ 0.70 \$ (0.01) \$ (0.02)	

USANA Health Sciences, Inc. Consolidated Balance Sheets (in thousands)

Weighted average shares outstanding - diluted 18,486

As of As of 30-Dec-06 29-Sep-07

(Unaudited)

\$ 0.55 \$ 0.68

16,613

ASSETS

Current Assets

Net Earnings

 Cash and cash equivalents
 \$ 27,029 \$ 11,718

 Inventories
 22,483 21,058

 Other current assets
 11,103 12,841

Total current assets 60,615 45,617

Property and equipment, net Goodwill 5,690 5,690 Other assets 3,374 4,503 45,838

Total assets \$ 100,002 \$ 101,648

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities

Accounts payable \$ 10,241 \$ 7,910 Other current liabilities 29,564 32,507 Total current liabilities 39,805 40,417 Long-term liabilities Line of Credit 34,625 Other long-term liabilities - 1,673 Stockholders' equity 24,933 Total liabilities and stockholders' equity \$ 100,002 \$ 101,648 USANA Health Sciences, Inc. Sales by Region (in thousands) Quarter Ended 30-Sep-06 29-Sep-07 _____ (Unaudited) (Unaudited) Region North America \$39,425 42.9% \$42,455 40.0% United States 16,574 18.0% 18,792 17.7% Canada 4,503 4.9% 5,372 5.1% Mexico -----60,502 65.8% \$ 66,619 62.8% North America Total Asia Pacific

 Australia-New Zealand
 12,297
 13.4%
 14,163

 Hong Kong
 4,582
 5.0%
 6,876
 6.5%

 Japan
 2,357
 2.5%
 2,395
 2.3%

 12,297 13.4% 14,163 13.3% 5,509 6.0% 5,354 5.0% Taiwan South Korea 2,117 2.3% 1,634 1.5% 4,603 5.0% 4,209 4.0% Singapore Malaysia - 0.0% 4,931 4.6% Asia Pacific Total 31,465 34.2% 39,562 37.2% \$91,967 100.0% \$106,181 100.0% Consolidated Active Associates by Region As of 30-Sep-06 29-Sep-07 (Unaudited) (Unaudited) Region North America United States 58,000 40.0% 63,000 35.0% Canada 22,000 15.2% 28,000 15.5% 10,000 6.9% 14,000 7.8% Mexico North America Total 90,000 62.1% 105,000 58.3% Asia Pacific Australia-New Zealand 18,000 12.4% 21,000 11.7% Hong Kong 8,000 5.5% 13,000 7.2% Japan 4,000 2.7% 5,000 2.8% Taiwan 13,000 9.0% 14,000 7.8% South Korea 2,000 1.4% 2,000 1.1% Singapore 10,000 6.9% 8,000 4.4% Malaysia - 0.0% 12,000 6.7%

55,000 37.9% 75,000 41.7%

Asia Pacific Total

145,000 100.0% 180,000 100.0% ____ ___

Active Preferred Customers by Region

As of	
30-Sep-06	29-Sep-07
(Unaudited)	(Unaudited)

Region

North America

United States 49,000 64.5% 51,000 64.6% 18,000 23.7% 17,000 21.5% Canada Mexico 2,000 2.6% 3,000 3.8%

North America Total 69,000 90.8% 71,000 89.9%

Asia Pacific

sia Pacitic
Australia-New Zealand

6,000 7.9% 0,000

** 0.0% 1,000 1.3% 6,000 7.9% 6,000 7.5% 1,000 1.3% 1,000 1.3% Japan Taiwan ** 0.0% ** 0.0% ** 0.0% ** 0.0% South Korea ** 0.0% ** 0.0% Singapore ** 0.0% Malaysia - 0.0%

Asia Pacific Total

7,000 9.2% 8,000 10.1%

Total

76,000 100.0% 79,000 100.0%

CONTACT: USANSA Health Sciences

Investor Relations:

Riley Timmer, 801-954-7922 investor.relations@us.usana.com

or

Edelman

Joe Poulos, 312-240-2719

^{**} Count of Active Preferred Customers is less than 500.